Biofrontera Inc (BFRI)

Currency in USD
0.8700
+0.0144(+1.68%)
Closed·
0.8680-0.0020(-0.23%)
·
BFRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.80150.8790
52 wk Range
0.53601.1900
Key Statistics
Prev. Close
0.8556
Open
0.864
Day's Range
0.8015-0.879
52 wk Range
0.536-1.19
Volume
192.52K
Average Volume (3m)
474.87K
1-Year Change
1.1628%
Book Value / Share
0.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BFRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.0000
Upside
+589.66%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Biofrontera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Employees
93

Biofrontera Inc Earnings Call Summary for Q4/2025

  • Biofrontera reported record Q4 2025 revenue of $17.1M, up 36% YoY, and achieved first profitable quarter with $5.6M net income.
  • Strategic transaction with Biofrontera AG drove 45% decrease in COGS and improved gross profit margin to 82% from 58% in Q4 2024.
  • Adjusted EBITDA reached $4.9M with 29% margin; company expects full annualized cost structure benefits to materialize in 2026.
  • Stock rose 7.07% to $0.93 in premarket trading, reflecting investor confidence in operational efficiency and expanded product pipeline.
  • Management projects continued revenue growth driven by pending FDA approvals for new Ameluz indications and enhanced market position in photodynamic therapy.
Last Updated: 2026-03-19, 10:52 a/m
Read Full Transcript

Compare BFRI to Peers and Sector

Metrics to compare
BFRI
Peers
Sector
Relationship
P/E Ratio
−1.0x−18.3x−0.5x
PEG Ratio
−0.010.050.00
Price/Book
1.0x1.7x2.6x
Price / LTM Sales
0.2x2.2x3.1x
Upside (Analyst Target)
-94.0%57.6%
Fair Value Upside
Unlock18.4%8.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.0000
(+589.66% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy3.00+244.83%3.00MaintainNov 14, 2025
Benchmark
Buy3.00+244.83%3.00MaintainOct 03, 2025
Benchmark
Buy2.75+216.09%7.00MaintainMay 19, 2025
Benchmark
Buy7.00+704.60%-MaintainMar 24, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.62 / -0.57
Revenue / Forecast
6.99M / --
EPS Revisions
Last 90 days

BFRI Income Statement

People Also Watch

0.482
MOBX
-14.54%
2.24
ELPW
-7.44%
0.8481
CISS
-1.93%
10.940
ASYS
-5.45%
0.560
OLB
-3.45%

FAQ

What Is the Biofrontera (BFRI) Stock Price Today?

The Biofrontera stock price today is 0.8700 USD.

What Stock Exchange Does Biofrontera Trade On?

Biofrontera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biofrontera?

The stock symbol for Biofrontera is "BFRI."

What Is the Biofrontera Market Cap?

As of today, Biofrontera market cap is 10.1300M USD.

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -0.9050.

From a Technical Analysis Perspective, Is BFRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Biofrontera Stock Split?

Biofrontera has split 1 times.

How Many Employees Does Biofrontera Have?

Biofrontera has 93 employees.

What is the current trading status of Biofrontera (BFRI)?

As of Mar 21, 2026, Biofrontera (BFRI) is trading at a price of 0.8700 USD, with a previous close of 0.8556 USD. The stock has fluctuated within a day range of 0.8015 USD to 0.8790 USD, while its 52-week range spans from 0.5360 USD to 1.1900 USD.

What Is Biofrontera (BFRI) Price Target According to Analysts?

The average 12-month price target for Biofrontera is 6.0000 USD, with a high estimate of 9 USD and a low estimate of 3 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +589.66% Upside potential.

What Is the BFRI Premarket Price?

BFRI's last pre-market stock price is 0.8364 USD. The pre-market share volume is 8,270.0000, and the stock has decreased by -0.0192, or -2.2400%.

What Is the BFRI After Hours Price?

BFRI's last after hours stock price is 0.8680 USD, the stock has decreased by -0.0020, or -0.2300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.